TNFRSF10B and neoplasm: In addition, we also confirmed that triple-negative breast cancer cells (MDA-MB-468, MDA-MB-436) revealed an increase in DR5 expression after Olaparib treatment (Fig. 3E and 3F), suggesting that the mechanism of DR5 up-regulation is not only applicable to GBM but also to other tumor entities.